Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2019

LACTOBACILLUS REUTERI – AN ALTERNATIVE IN THE FIRST-LINE OF HELICOBACTER PYLORI ERADICATION

CĂTĂLINA MIHAI 1, BOGDAN MIRCEA MIHAI 2*, MIHAELA DRANGA 1, ANCA CARDONEANU 3, CRISTINA CIJEVSCHI PRELIPCEAN 1

1.Institute of Gastroenterology and Hepatology, “Grigore T. Popa” University of Medicine and Pharmacy, “Sf. Spiridon” Clinical Hospital, Iași, Romania
2 .Clinical Centre of Diabetes, Nutrition and Metabolic Disease, “Grigore T. Popa” University of Medicine and Pharmacy, “Sf. Spiridon” Clinical Hospital, Iași, Romania
3 .Rheumatology, “Grigore T. Popa” University of Medicine and Pharmacy, Rehabilitation Clinical Hospital, Iași, Romania

Download Full Article PDF

In the context of reduced effectiveness of classical antibiotic regimens in eradicating Helicobacter pylori infection, it is justified to search for alternative therapies. The present study included 70 patients diagnosed with Helicobacter pylori infection by the rapid urease test, randomized into two therapeutic regimens: Lactobacillus reuteri DSMZ17648, liquorice and calcium carbonate and classical proton pump inhibitor - amoxicillin – clarithromycin scheme. The eradication efficiency was 54.3% in the Lactobacillus reuteri group vs 77.1% in the antibiotic group (p = 0.042) but with a significantly lower rate of side effects (2.9% vs 17.1%, p = 0.037). Finding new drugs to eradicate Helicobacter pylori with increased efficacy, costeffectiveness ratio and no side effects remains a challenge.